Number of pay-for-delay deals remains low, says FTC
07-12-2020
Seventh Circuit urged to review AbbVie antitrust ruling
15-10-2020
AG advises CJEU to uphold €94 million pay-for-delay fine
05-06-2020
madamF / Shutterstock.com
The European Commission has fined Teva and its subsidiary Cephalon €60.5 million ($72 million) for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
European Commission, Teva, Cephalon, generics, pay-for-delay, competition law, patents, modafinil, fines
